ISRG
Intuitive Surgical, Inc.554.58
-4.94-0.88%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
Cardiac TAM: 160k procedures quantified
Q&A quantified the cardiac TAM for da Vinci 5 at 160,000 annual procedures in cleared markets, up from 17,000 last year on legacy systems. Management detailed My Intuitive+ subscription renewals kicking in Q2 2026, with surgeon value dictating rates and pricing. They expressed confidence countering China tender pricing via local manufacturing, while ramping XiR for ASC benign procedures like cholecystectomies. No Q4 pull-forward emerged from subsidy risks. XiR margins remain healthy. Watch cardiac adoption and subscription traction.
Key Stats
Market Cap
198.80BP/E (TTM)
73.55Basic EPS (TTM)
7.54Dividend Yield
0%Recent Filings
8-K
Acquisition expands European ops
Intuitive Surgical completed its acquisition of the da Vinci and Ion distribution business from ab medica, Abex, Excelencia Robótica, and affiliates on March 1, 2026. This launches direct operations in Italy, Spain, Portugal, Malta, and San Marino, integrating 250 employees and over 470 da Vinci systems installed as of December 31, 2025. Direct control sharpens customer support. Integration risks loom.
10-K
FY2025 results
Intuitive Surgical's FY2025 10-K shows robust procedure growth but lacks quarterly breakdowns. Da Vinci procedures hit 3.2M, up 18% y/y, with U.S. general surgery accelerating 18% on cholecystectomies and hernias while bariatrics dipped. Ion biopsies surged 51% to 144K amid 24% installed base growth to 995 systems. Systems placed totaled 1,721 (up 13%), including 870 da Vinci 5s; recurring revenue hit 84% of $10.1B total (up 21%). No Q4 metrics disclosed. Cash swelled to $9B on $3B ops cash, funding $2.3B buybacks. Highly competitive landscape threatens momentum.
8-K
Q4 revenue surges 19%
8-K
Q4 revenue up 19%, da Vinci 5 booms
Intuitive Surgical released preliminary Q4 2025 results showing $2.87B revenue, up 19% from $2.41B in Q4 2024, driven by 18% procedure growth and 532 da Vinci system placements—including 303 da Vinci 5 units. Full-year revenue hit $10.06B, up 21%, with da Vinci procedures at 3.153 million, up 18%, fueled by U.S. general surgery and OUS expansion. Da Vinci 5 adoption surges. Expect 13-15% procedure growth in 2026; results preliminary pending audit.
8-K
Miller shifts to AI strategy role
IPO
Website
Employees
Sector
Industry
BDX
Becton, Dickinson and Company
196.39-3.70
ECIA
Encision, Inc.
0.15+0.00
HOLX
Hologic, Inc.
75.02-0.17
IART
Integra LifeSciences Holdings C
13.00-0.47
ICUI
ICU Medical, Inc.
147.07-0.96
MMSI
Merit Medical Systems, Inc.
86.85+0.44
RBOT
Vicarious Surgical Inc.
2.43-0.04
SOLV
Solventum Corporation
80.59-1.30
SSII
SS Innovations International In
5.50+0.41
STXS
Stereotaxis, Inc.
2.38+0.06